Caris Q3 Profit Falls On Higher Expenses; Raises FY26 Revenue Guidance After 27% Revenue Growth
Caris Life Sciences (CAI) reported a 27% revenue increase in Q3 2026, but net income fell to $15.25M from $24.32M YoY due to higher expenses. Adjusted EBITDA also declined. The company raised FY26 revenue guidance to $1.04B-$1.05B, up 28-29% YoY. Shares were down 12.85% in overnight trading.
How this was made
The 30-second read
Why it matters
The earnings miss could trigger short‑term downside, yet the upgraded guidance may support a rebound.
Market read
First‑time earnings disclosure with material guidance lift; relevant for biotech and precision‑medicine investors.
What to watch
Cash position of $767M provides ample runway for R&D and potential acquisitions.
Background
Caris Life Sciences released its Q3 2026 earnings, reporting a profit decline but strong revenue growth and higher full‑year guidance.
Ticker impact
Q3 net income fell to $15.25M and revenue rose 27% to $275.36M, while FY26 revenue guidance was raised to $1.04‑$1.05B.
likely pressure as investors weigh lower profit against raised guidance
The drop in earnings may trigger short‑term selling, but the upgraded revenue outlook could attract buyers, creating mixed short‑term price action.
Market effects
Highlights continued demand for molecular profiling services in the TechBio sector.
U.S. biotech stocks may see modest volatility following the report.
Revenue growth underscores broader trend of personalized medicine adoption worldwide.
Counterpoint
The raised guidance may outweigh the earnings miss, offering a buying opportunity on dip.
Key entities
- companyCaris Life Sciences, Inc.
U.S. biotech firm providing molecular profiling services.
